Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8

Journal of Immunology

Volumn 190, Issue 1, 2013, Pages 205-210

  Yu, Xiaocong ^a,b   Duval, Mark ^a   Lewis, Christopher ^a   Gawron, Melissa A ^a   Wang, Rijian ^a,b   Posner, Marshall R ^a,b,c   Cavacini, Lisa A ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F425A1G8; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; MUCOSA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN ISOTYPES; NEUTRALIZATION TESTS;

EID: 84871846348     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201469     Document Type: Article

References (53)

1. Willey, S., and M. M. Aasa-Chapman. 2008. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol. 16: 596-604.
2. Zhou, J. Y., and D. C. Montefiori. 1997. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71: 2512-2517.
3. Bailey, J. R., K. G. Lassen, H.-C. Yang, T. C. Quinn, S. C. Ray, J. N. Blankson, and R. F. Siliciano. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80: 4758-4770.
4. Palker, T. J., M. E. Clark, A. J. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and B. F. Haynes. 1988. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85: 1932-1936. (Pubitemid 24315798)
5. Posner, M. R., H. Elboim, and D. Santos. 1987. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 6: 611-625. (Pubitemid 18051305)
6. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320: 760-764. (Pubitemid 351929619)
7. Fowke, K. R., N. J. Nagelkerke, J. Kimani, J. N. Simonsen, A. O. Anzala, J. J. Bwayo, K. S. MacDonald, E. N. Ngugi, and F. A. Plummer. 1996. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348: 1347-1351. (Pubitemid 26383775)
8. Broliden, K., J. Hinkula, C. Devito, P. Kiama, J. Kimani, D. Trabbatoni, J. J. Bwayo, M. Clerici, F. Plummer, and R. Kaul. 2001. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol. Lett. 79: 29-36. (Pubitemid 32938205)
9. Kaul, R., D. Trabattoni, J. J. Bwayo, D. Arienti, A. Zagliani, F. M. Mwangi, C. Kariuki, E. N. Ngugi, K. S. MacDonald, T. B. Ball, et al. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13: 23-29. (Pubitemid 29078060)
10. Beyrer, C., A. W. Artenstein, S. Rugpao, H. Stephens, T. C. VanCott, M. L. Robb, M. Rinkaew, D. L. Birx, C. Khamboonruang, P. A. Zimmerman, et al; Chiang Mai HEPS Working Group. 1999. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J. Infect. Dis. 179: 59-67. (Pubitemid 29028339)
11. Mazzoli, S., D. Trabattoni, S. Lo Caputo, S. Piconi, C. Ble?, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, et al. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3: 1250-1257. (Pubitemid 27508826)
12. Lo Caputo, S., D. Trabattoni, F. Vichi, S. Piconi, L. Lopalco, M. L. Villa, F. Mazzotta, and M. Clerici. 2003. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 17: 531-539. (Pubitemid 36293106)
13. Devito, C., J. Hinkula, R. Kaul, L. Lopalco, J. J. Bwayo, F. Plummer, M. Clerici, and K. Broliden. 2000. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14: 1917-1920.
14. Devito, C., J. Hinkula, R. Kaul, J. Kimani, P. Kiama, L. Lopalco, C. Barass, S. Piconi, D. Trabattoni, J. J. Bwayo, et al. 2002. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 30: 413-420. (Pubitemid 34857316)
15. Bélec, L., P. D. Ghys, H. Hocini, J. N. Nkengasong, J. Tranchot-Diallo, M. O. Diallo, V. Ettiègne-Traore, C. Maurice, P. Becquart, M. Matta, et al. 2001. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184: 1412-1422. (Pubitemid 33108855)
16. Devito, C., K. Broliden, R. Kaul, L. Svensson, K. Johansen, P. Kiama, J. Kimani, L. Lopalco, S. Piconi, J. J. Bwayo, et al. 2000. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165: 5170-5176.
17. Fiore, J. R., V. Laddago, A. Lepera, L. La Grasta, M. Di Stefano, A. Saracino, P. Lopalco, G. Pastore, and G. Angarano. 2000. Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. New Microbiol. 23: 85-92.
18. Mestecky, J., S. Jackson, Z. Moldoveanu, L. R. Nesbit, R. Kulhavy, S. J. Prince, S. Sabbaj, M. J. Mulligan, and P. A. Goepfert. 2004. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 20: 972-988. (Pubitemid 39369704)
19. Raux, M., L. Finkielsztejn, D. Salmon-Céron, H. Bouchez, J. L. Excler, E. Dulioust, J. M. Grouin, D. Sicard, and C. Blondeau. 1999. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res. Hum. Retroviruses 15: 1365-1376. (Pubitemid 29480746)
20. Mestecky, J., P. F. Wright, L. Lopalco, H. F. Staats, P. A. Kozlowski, Z. Moldoveanu, R. C. Alexander, R. Kulhavy, C. Pastori, L. Maboko, et al. 2011. Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res. Hum. Retroviruses 27: 469-486.
21. Dorrell, L., A. J. Hessell, M. Wang, H. Whittle, S. Sabally, S. Rowland-Jones, D. R. Burton, and P. W. Parren. 2000. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 14: 1117-1122. (Pubitemid 30420654)
22. Alexander, R., and J. Mestecky. 2007. Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr. HIV Res. 5: 588-593. (Pubitemid 351210993)
23. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366: 1275-1286.
24. Cavacini, L., M. Duval, L. Song, R. Sangster, S. H. Xiang, J. Sodroski, and M. Posner. 2003. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS 17: 685-689. (Pubitemid 36521074)
25. Yu, X., D. Pollock, M. Duval, C. Lewis, K. Joseph, H. Meade, and L. Cavacini. 2012. Neutralization of HIV by milk expressed antibody. J. Acquir. Immune Defic. Syndr. In press. 10.1097/QAI.0b013e318271c450.
26. Cavacini, L. A., D. Kuhrt, M. Duval, K. Mayer, and M. R. Posner. 2003. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res. Hum. Retroviruses 19: 785-792. (Pubitemid 37215134)
27. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46: 1896-1905. (Pubitemid 34535213)
28. Duval, M., M. R. Posner, and L. A. Cavacini. 2008. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J. Virol. 82: 4671-4674. (Pubitemid 351563705)
29. Miranda, L. R., M. Duval, H. Doherty, M. S. Seaman, M. R. Posner, and L. A. Cavacini. 2007. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain. J. Immunol. 178: 7132-7138. (Pubitemid 46847439)
30. Cavacini, L., J. Peterson, E. Nappi, M. Duval, R. Goldstein, K. Mayer, and M. Posner. 1999. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals. J. Virol. 73: 9638-9641. (Pubitemid 29487123)
31. Stubbe, H., J. Berdoz, J.-P. Kraehenbuhl, and B. Corthésy. 2000. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J. Immunol. 164: 1952-1960. (Pubitemid 30108750)
32. Fouts, T. R., R. Tuskan, K. Godfrey, M. Reitz, D. Hone, G. K. Lewis, and A. L. DeVico. 2000. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 74: 11427-11436. (Pubitemid 32222289)
33. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178: 6596-6603. (Pubitemid 46717444)
34. Hernandez-Ilizaliturri, F. J., V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman. 2003. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin. Cancer Res. 9: 5866-5873. (Pubitemid 38018069)
35. Rafiq, K., A. Bergtold, and R. Clynes. 2002. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110: 71-79. (Pubitemid 34743467)
36. Choe, H., W. Li, P. L. Wright, N. Vasilieva, M. Venturi, C.-C. Huang, C. Grundner, T. Dorfman, M. B. Zwick, L. Wang, et al. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114: 161-170. (Pubitemid 36936910)
37. Moulard, M., S. K. Phogat, Y. Shu, A. F. Labrijn, X. Xiao, J. M. Binley, M. Y. Zhang, I. A. Sidorov, C. C. Broder, J. Robinson, et al. 2002. Broadly crossreactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. USA 99: 6913-6918. (Pubitemid 34526232)
38. Boehm, M. K., J. M. Woof, M. A. Kerr, and S. J. Perkins. 1999. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J. Mol. Biol. 286: 1421-1447. (Pubitemid 29121726)
39. Bakema, J. E., and M. van Egmond. 2011. Immunoglobulin A: A next generation of therapeutic antibodies? MAbs 3: 352-361.
40. Otten, M. A., E. Rudolph, M. Dechant, C. W. Tuk, R. M. Reijmers, R. H. Beelen, J. G. van de Winkel, and M. van Egmond. 2005. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J. Immunol. 174: 5472-5480. (Pubitemid 40593187)
41. Huls, G., I. A. Heijnen, E. Cuomo, J. van der Linden, E. Boel, J. G. van de Winkel, and T. Logtenberg. 1999. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 59: 5778-5784.
42. Dechant, M., and T. Valerius. 2001. IgA antibodies for cancer therapy. Crit. Rev. Oncol. Hematol. 39: 69-77. (Pubitemid 32564867)
43. Ma, J. K., B. Y. Hikmat, K. Wycoff, N. D. Vine, D. Chargelegue, L. Yu, M. B. Hein, and T. Lehner. 1998. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat. Med. 4: 601-606. (Pubitemid 28237360)
44. Woof, J. M., and D. R. Burton. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4: 89-99. (Pubitemid 38209203)
45. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290. (Pubitemid 32368037)
46. Wolfe, D. N., G. S. Kirimanjeswara, E. M. Goebel, and E. T. Harvill. 2007. Comparative role of immunoglobulin A in protective immunity against the Bordetellae. Infect. Immun. 75: 4416-4422. (Pubitemid 47378099)
47. Lohse, S., S. Derer, T. Beyer, K. Klausz, M. Peipp, J. H. Leusen, J. G. van de Winkel, M. Dechant, and T. Valerius. 2011. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J. Immunol. 186: 3770-3778.
48. Bakema, J. E., S. H. Ganzevles, D. M. Fluitsma, M. W. Schilham, R. H. Beelen, T. Valerius, S. Lohse, M. J. Glennie, J. P. Medema, and M. van Egmond. 2011. Targeting FcaRI on polymorphonuclear cells induces tumor cell killing through autophagy. J. Immunol. 187: 726-732.
49. van der Pol, W., G. Vidarsson, H. A. Vilé, J. G. van de Winkel, and M. E. Rodriguez. 2000. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). J. Infect. Dis. 182: 1139-1145.
50. Iagudaeva, E. Iu., L. S. Zhigis, O. A. Razguliaeva, V. S. Zueva, E. E. Mel'nikov, V. P. Zubov, L. V. Kozlov, A. M. Bichucher, O. V. Kotel'nikova, A. P. Alliluev, et al. 2010. [Isolation and determination of activity of IgA1 protease from Neisseria meningitidis]. Bioorg. Khim. 36: 89-97.
51. Vidarsson, G., W. L. van Der Pol, J. M. van Den Elsen, H. Vilé, M. Jansen, J. Duijs, H. C. Morton, E. Boel, M. R. Daha, B. Corthésy, and J. G. van De Winkel. 2001. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J. Immunol. 166: 6250-6256. (Pubitemid 32440757)
52. Hellwig, S. M., A. B. van Spriel, J. F. Schellekens, F. R. Mooi, and J. G. van de Winkel. 2001. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect. Immun. 69: 4846-4850. (Pubitemid 32674464)
53. Balu, S., R. Reljic, M. J. Lewis, R. J. Pleass, R. McIntosh, C. van Kooten, M. van Egmond, S. Challacombe, J. M. Woof, and J. Ivanyi. 2011. A novel human IgA monoclonal antibody protects against tuberculosis. J. Immunol. 186: 3113-3119.